STAAR Surgical Company

NasdaqGM:STAA Rapport sur les actions

Capitalisation boursière : US$1.9b

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

STAAR Surgical Gestion

Gestion contrôle des critères 0/4

Le PDG STAAR Surgical's est Tom Frinzi, nommé en Jan2023, a un mandat de 1.58 ans. La rémunération annuelle totale est $ 10.22M, composée du salaire de 7.7% et des bonus 92.3%, y compris les actions et options de la société. détient directement 0.046% des actions de la société, d'une valeur de $ 862.71K. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 1.6 ans et 2.9 ans.

Informations clés

Tom Frinzi

Directeur général

US$10.2m

Rémunération totale

Pourcentage du salaire du PDG7.7%
Durée du mandat du directeur général1.6yrs
Propriété du PDG0.05%
Durée moyenne d'occupation des postes de direction1.6yrs
Durée moyenne du mandat des membres du conseil d'administration2.9yrs

Mises à jour récentes de la gestion

Recent updates

Results: STAAR Surgical Company Exceeded Expectations And The Consensus Has Updated Its Estimates

Aug 10
Results: STAAR Surgical Company Exceeded Expectations And The Consensus Has Updated Its Estimates

STAAR Surgical Company's (NASDAQ:STAA) Popularity With Investors Is Clear

Aug 05
STAAR Surgical Company's (NASDAQ:STAA) Popularity With Investors Is Clear

The Returns At STAAR Surgical (NASDAQ:STAA) Aren't Growing

Jul 12
The Returns At STAAR Surgical (NASDAQ:STAA) Aren't Growing

Is There Now An Opportunity In STAAR Surgical Company (NASDAQ:STAA)?

May 27
Is There Now An Opportunity In STAAR Surgical Company (NASDAQ:STAA)?

Market Participants Recognise STAAR Surgical Company's (NASDAQ:STAA) Revenues Pushing Shares 30% Higher

Apr 26
Market Participants Recognise STAAR Surgical Company's (NASDAQ:STAA) Revenues Pushing Shares 30% Higher

STAAR Surgical Stock: I Don't See A Great Path Forward, Despite The Recent Surge

Apr 05

STAAR Surgical (NASDAQ:STAA) Shareholders Will Want The ROCE Trajectory To Continue

Mar 25
STAAR Surgical (NASDAQ:STAA) Shareholders Will Want The ROCE Trajectory To Continue

STAAR Surgical Company: Potential Buy After Long-Term Valuation Downgrade

Mar 13

STAAR Surgical Company (NASDAQ:STAA) Looks Just Right With A 28% Price Jump

Mar 07
STAAR Surgical Company (NASDAQ:STAA) Looks Just Right With A 28% Price Jump

Is There Now An Opportunity In STAAR Surgical Company (NASDAQ:STAA)?

Jan 31
Is There Now An Opportunity In STAAR Surgical Company (NASDAQ:STAA)?

With STAAR Surgical Company (NASDAQ:STAA) It Looks Like You'll Get What You Pay For

Jan 05
With STAAR Surgical Company (NASDAQ:STAA) It Looks Like You'll Get What You Pay For

Returns On Capital Are Showing Encouraging Signs At STAAR Surgical (NASDAQ:STAA)

Nov 30
Returns On Capital Are Showing Encouraging Signs At STAAR Surgical (NASDAQ:STAA)

Is There An Opportunity With STAAR Surgical Company's (NASDAQ:STAA) 21% Undervaluation?

Nov 12
Is There An Opportunity With STAAR Surgical Company's (NASDAQ:STAA) 21% Undervaluation?

Is STAAR Surgical Company (NASDAQ:STAA) Potentially Undervalued?

Oct 25
Is STAAR Surgical Company (NASDAQ:STAA) Potentially Undervalued?

Returns On Capital At STAAR Surgical (NASDAQ:STAA) Have Hit The Brakes

Aug 24
Returns On Capital At STAAR Surgical (NASDAQ:STAA) Have Hit The Brakes

Are STAAR Surgical Company (NASDAQ:STAA) Investors Paying Above The Intrinsic Value?

Jul 02
Are STAAR Surgical Company (NASDAQ:STAA) Investors Paying Above The Intrinsic Value?

Is Now The Time To Look At Buying STAAR Surgical Company (NASDAQ:STAA)?

Jun 17
Is Now The Time To Look At Buying STAAR Surgical Company (NASDAQ:STAA)?

Here's Why We Think STAAR Surgical (NASDAQ:STAA) Might Deserve Your Attention Today

May 13
Here's Why We Think STAAR Surgical (NASDAQ:STAA) Might Deserve Your Attention Today

A Look At The Fair Value Of STAAR Surgical Company (NASDAQ:STAA)

Mar 26
A Look At The Fair Value Of STAAR Surgical Company (NASDAQ:STAA)

STAAR Surgical (NASDAQ:STAA) Is Looking To Continue Growing Its Returns On Capital

Mar 12
STAAR Surgical (NASDAQ:STAA) Is Looking To Continue Growing Its Returns On Capital

Should You Investigate STAAR Surgical Company (NASDAQ:STAA) At US$68.56?

Feb 13
Should You Investigate STAAR Surgical Company (NASDAQ:STAA) At US$68.56?

Here's Why We Think STAAR Surgical (NASDAQ:STAA) Might Deserve Your Attention Today

Jan 28
Here's Why We Think STAAR Surgical (NASDAQ:STAA) Might Deserve Your Attention Today

Calculating The Fair Value Of STAAR Surgical Company (NASDAQ:STAA)

Dec 15
Calculating The Fair Value Of STAAR Surgical Company (NASDAQ:STAA)

The Return Trends At STAAR Surgical (NASDAQ:STAA) Look Promising

Dec 01
The Return Trends At STAAR Surgical (NASDAQ:STAA) Look Promising

What Is STAAR Surgical Company's (NASDAQ:STAA) Share Price Doing?

Oct 26
What Is STAAR Surgical Company's (NASDAQ:STAA) Share Price Doing?

Keep Adding To STAAR Surgical Longs, Buy Thesis Remains

Sep 20

Should You Be Adding STAAR Surgical (NASDAQ:STAA) To Your Watchlist Today?

Sep 05
Should You Be Adding STAAR Surgical (NASDAQ:STAA) To Your Watchlist Today?

STAAR Surgical Company (NASDAQ:STAA) Shares Could Be 24% Above Their Intrinsic Value Estimate

Aug 21
STAAR Surgical Company (NASDAQ:STAA) Shares Could Be 24% Above Their Intrinsic Value Estimate

STAAR Surgical rises 15% on Q2 result beat

Aug 11

Should You Think About Buying STAAR Surgical Company (NASDAQ:STAA) Now?

Jul 20
Should You Think About Buying STAAR Surgical Company (NASDAQ:STAA) Now?

STAAR Surgical: Hard Data Approach Justifies Long-Only Portfolio Allocation

Jul 05

Analyse de la rémunération des PDG

Comment la rémunération de Tom Frinzi a-t-elle évolué par rapport aux bénéfices de STAAR Surgical?
DateRémunération totaleSalaireBénéfices de l'entreprise
Jun 28 2024n/an/a

US$17m

Mar 29 2024n/an/a

US$15m

Dec 29 2023US$10mUS$788k

US$21m

Sep 29 2023n/an/a

US$19m

Jun 30 2023n/an/a

US$26m

Mar 31 2023n/an/a

US$33m

Dec 30 2022US$274kn/a

US$40m

Sep 30 2022n/an/a

US$38m

Jul 01 2022n/an/a

US$34m

Apr 01 2022n/an/a

US$29m

Dec 31 2021US$250kn/a

US$28m

Oct 01 2021n/an/a

US$23m

Jul 02 2021n/an/a

US$21m

Apr 02 2021n/an/a

US$11m

Jan 01 2021US$182kn/a

US$6m

Rémunération vs marché: La rémunération totale de Tom ($USD 10.22M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 5.62M ).

Rémunération et revenus: La rémunération de Tom a augmenté de plus de 20 % tandis que les bénéfices de l'entreprise ont chuté de plus de 20 % au cours de l'année écoulée.


PDG

Tom Frinzi (68 yo)

1.6yrs

Titularisation

US$10,220,581

Compensation

Mr. Thomas G. Frinzi, also known as Tom, serves as Executive Chairman of the Board at ViaLase, Inc. since November 2022 and joined the company in November 2022. He serves as Executive Chair at Aurion Biote...


Équipe de direction

NomPositionTitularisationCompensationPropriété
Thomas Frinzi
President1.6yrsUS$10.22m0.046%
$ 862.7k
Patrick Williams
Chief Financial Officer4.1yrsUS$2.82m0.070%
$ 1.3m
Warren Foust
Chief Operating Officer1.3yrsUS$3.42m0.0089%
$ 165.2k
Keith Holliday
Chief Technology Officer7.4yrsUS$2.41m0.036%
$ 673.9k
Scott Barnes
Chief Medical Officer6.8yrsUS$2.48m0.064%
$ 1.2m
Brian Moore
Vice President of Investor Relations & Corporate Developmentno datapas de donnéespas de données
Nathaniel Sisitsky
General Counsel & Corporate Secretaryless than a yearpas de donnéespas de données
Nancy Sabin
Chief Marketing Officerless than a yearpas de donnéespas de données
James Francese
Senior Vice President of Commercial Operations - North America & APAC7.8yrsUS$2.54m0.060%
$ 1.1m
Magda Michna
Chief Clinical1.3yrspas de données0.0061%
$ 114.3k
Robert Studholme
Senior Vice President of Operationsno datapas de données0.066%
$ 1.2m

1.6yrs

Durée moyenne de l'emploi

60.5yo

Âge moyen

Gestion expérimentée: L'équipe de direction de STAA n'est pas considérée comme expérimentée (ancienneté moyenne 1.6 ans), ce qui suggère une nouvelle équipe.


Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
Thomas Frinzi
President4.2yrsUS$10.22m0.046%
$ 862.7k
Stephen Farrell
Lead Independent Director8.6yrsUS$294.87k0.031%
$ 574.5k
Aimee Weisner
Independent Director2.2yrsUS$259.96k0.031%
$ 582.0k
Lilian Zhou
Independent Directorless than a yearUS$99.69k0.0093%
$ 173.4k
Brian Williams
Member of Optometric Advisory Council15.8yrspas de donnéespas de données
Arthur Crosswell Butcher
Independent Directorless than a yearpas de données0.0059%
$ 109.6k
Wei Jiang
Independent Directorless than a yearpas de données0.0072%
$ 134.4k
Elizabeth Lin
Independent Director3.6yrsUS$249.99k0.010%
$ 193.3k

2.9yrs

Durée moyenne de l'emploi

55yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de STAA ne sont pas considérés comme expérimentés (ancienneté moyenne 2.9 ans), ce qui suggère un nouveau conseil d'administration.